Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEAM5) is a protein belonging to the carcinoembryonic antigen (CEA) family, playing a vital role in cell adhesion and signaling. It is notably overexpressed in various cancers, such as colorectal cancer and non-small-cell lung cancer (NSCLC). This overexpression in tumor cells compared to normal tissues creates opportunities for targeted therapies. Researchers are developing CEAM5-targeted treatments, including monoclonal antibodies and antibody-drug conjugates, designed to specifically attack and destroy cancer cells. Additionally, CEAM5 is a valuable diagnostic biomarker, aiding in cancer diagnosis, monitoring progression, and evaluating treatment responses. Its significant role in both therapy and diagnostics underscores its potential to enhance personalized cancer treatment and improve patient outcomes.
